flecainide acetate oral inhalation solution (FlecIH-103) / InCarda  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
flecainide acetate oral inhalation solution (FlecIH-103) / InCarda
ACTRN12624000223538: A Phase 1 Study of FlecIH-103 (Flecainide Acetate Inhalation Solution) Administered Using an Investigational, Single Use, Vibrating Mesh Nebulizer Delivery System to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

Not yet recruiting
1
44
 
InCarda Therapeutics Australia, Pty. Ltd, InCarda Therapeutics Australia, Pty, Ltd
Atrial Fibrilation
 
 
ACTRN12618001239257: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FlecIH-101 Versus Placebo in Healthy Volunteers

Completed
1
21
 
InCarda Therapeutics Australia, Pty, Ltd, InCarda Therapeutics Australia, Pty, Ltd
Paroxysmal atrial fibrillation
 
 
ACTRN12620000461998: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FlecIH-104 in Healthy Volunteers

Completed
1
18
 
InCarda Therapeutics Australia, Pty, Ltd, InCarda Therapeutics Australia, Pty, Ltd
Paroxysmal atrial fibrillation
 
 
ACTRN12621000718842: A Phase 1, Open-Label, Randomized, Single Dose Study of Flecainide Acetate Inhalation Solution (FlecIH-103) to Flecainide Acetate Intravenous Infusion (Tambocor®) to Compare Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

Completed
1
18
 
InCarda Therapeutics Australia Pty Ltd., InCarda Therapeutics Australia Pty Ltd.
Atrial Fibrillation
 
 

Download Options